Clinical Scorecard: Eliminating SHRM May Improve Visual Outcomes
At a Glance
| Category | Detail |
|---|---|
| Condition | Subretinal Hyperreflective Material (SHRM) |
| Key Mechanisms | SHRM is located between photoreceptors and RPE, associated with type 2 neovascularization and subretinal hemorrhage. |
| Target Population | Patients with conditions leading to SHRM, such as neovascular age-related macular degeneration. |
| Care Setting | Ophthalmology clinics and research settings. |
Key Highlights
- SHRM is a significant predictor of visual outcomes.
- Faricimab shows greater reduction in SHRM compared to aflibercept during the loading phase.
- Presence of SHRM at 12 weeks predicts vision over time.
- Eliminating SHRM early is crucial for optimal vision outcomes.
Guideline-Based Recommendations
Diagnosis
- Identify SHRM using OCT imaging.
Management
- Consider second-generation agents like faricimab for superior SHRM resolution.
Monitoring & Follow-up
- Assess SHRM volume and area at 12 weeks post-treatment.
Risks
- Potential development of fibrosis due to SHRM.
Patient & Prescribing Data
Patients with neovascular age-related macular degeneration or similar conditions.
Faricimab may provide better visual outcomes by reducing SHRM more effectively.
Clinical Best Practices
- Aim to eliminate SHRM as early as possible.
- Utilize OCT for ongoing assessment of SHRM.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
